Premium
Clinicopathologic study of large cell anaplastic lymphoma (ki‐1‐positive large cell lymphoma) among the japanese
Author(s) -
Nakamura Shigeo,
Takagi Norio,
Kitoh Kuniyoshi,
Suchi Taizan,
Kojima Masaru,
Motoori Tadashi,
Osada Hirotaka,
Takahashi Toshitada,
Suzuki Hisamitsu,
Ogura Michinori,
Kurita Soji,
Oyama Atsushi,
Ueda Ryuzo
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910701)68:1<118::aid-cncr2820680123>3.0.co;2-r
Subject(s) - anaplastic large cell lymphoma , lymphoma , medicine , pathology , large cell , pleomorphism (cytology) , lymph node , cd30 , cancer , immunohistochemistry , adenocarcinoma
The clinical, prognostic, phenotypic, and genotypic findings of 30 patients with large cell anaplastic lymphoma (Ki‐1‐positive large cell lymphoma) were analyzed. There were 13 male and 17 female patients (male‐female ratio, 0.8) whose ages ranged from 3 to 81 years of age (mean, 28 years of age; 67% of the patients younger than 30 years of age). The 5‐year survival rate was 52%; this was better than that of other types of high‐grade peripheral T‐cell lymphoma. Histologic examination showed distinctive morphologic features such as tumor cell pleomorphism, sinus infiltration, fibrosis, partial lymph node involvement, sparing of B‐cell regions, and occasional plasma cell infiltrates. Eighty percent of the cases were of T‐cell phenotype, and others expressed neither B‐cell nor T‐cell markers. The tumors were frequently positive for a histocompatibility antigen (HLA‐DR), CD25 (the interleukin‐2 receptor), and epithelial membrane antigen. Rearrangements of the T‐cell receptor beta gene were observed in nine of 13 cases (69%). These findings indicated that many of the tumors had the phenotype and genotype of activated T‐cells. This study also showed that large cell anaplastic lymphoma has a survival figure intermediate between Hodgkin's disease and low‐grade peripheral T‐cell lymphoma.